ERBB2 and breast cancer: Among receptor subtypes, hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2‐) BC detection decreased the most in 2020 (−10.4% [−13.8%, −7.0%]) but was within expected projections in 2021 (0.5%, [−3.3%, 4.2]).